Colm, following the 2015 BioInnovate program, cofounded Selio Medical with his teammate Garrett Ryan, a company which continues to develop a novel medical device to prevent pneumothorax during transthoracic needle biopsy. Utilising the Enterprise Ireland Commercialisation Fund mechanism to achieve substantial seed funding, the company has strived to accelerate its technology to market. As CEO, Colm has worked closely with Garrett (CTO) to leverage a number of incubating agencies including the prestigious National Science Foundation I-corps Accelerator Program in Georgia Tech, Atlanta and the industry leading Medtech Innovator Accelerator in San Francisco where they successfully achieved third place out of 600 entries. Selio Medical will spin out from Trinity College Dublin in late-2018 and are currently seeking a Series A investment of €2.5million to bring the technology to First in Human clinical trials in 2019.